Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBITDA (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of EBITDA data on record, last reported at -$50.3 million in Q4 2025.

  • For Q4 2025, EBITDA fell 661.21% year-over-year to -$50.3 million; the TTM value through Dec 2025 reached $22.6 million, up 319.57%, while the annual FY2025 figure was $22.6 million, 319.57% up from the prior year.
  • EBITDA reached -$50.3 million in Q4 2025 per TGTX's latest filing, down from $29.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $114.8 million in Q3 2023 and bottomed at -$92.9 million in Q4 2021.
  • Average EBITDA over 5 years is -$18.1 million, with a median of -$32.7 million recorded in 2022.
  • Peak YoY movement for EBITDA: soared 428.29% in 2023, then plummeted 661.21% in 2025.
  • A 5-year view of EBITDA shows it stood at -$92.9 million in 2021, then skyrocketed by 200.89% to $93.8 million in 2022, then crashed by 132.39% to -$30.4 million in 2023, then surged by 78.26% to -$6.6 million in 2024, then tumbled by 661.21% to -$50.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$50.3 million in Q4 2025, $29.4 million in Q3 2025, and $34.8 million in Q2 2025.